Nifurtimox

Nifurtimox, sold under the brand name Lampit, is a medication used to treat Chagas disease and sleeping sickness.[2][4] For sleeping sickness it is used together with eflornithine in nifurtimox-eflornithine combination treatment.[4] In Chagas disease it is a second-line option to benznidazole.[5] It is given by mouth.[2]

Quick facts: Clinical data, Trade names, Other names, AHFS... ▼

Nifurtimox

Clinical data
Trade names	Lampit[1]
Other names	Bayer 2502[2]
AHFS/Drugs.com	Drugs.com archive Lampit
License data	US DailyMed: Nifurtimox
Routes of administration	By mouth
ATC code	P01CC01 (WHO) QP51AC01 (WHO)
Legal status
Legal status	US: ℞-only[1][3] In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	Low
Metabolism	Liver (Cytochrome P450 oxidase (CYP) involved)
Elimination half-life	2.95 ± 1.19 hours
Excretion	Kidney, very low
Identifiers
IUPAC name N-(3-Methyl-1,1-dioxido-4-thiomorpholinyl)-1-(5-nitro-2-furyl)methanimine
CAS Number	23256-30-6 N
PubChem CID	6842999
DrugBank	DB11820 Y
ChemSpider	29464 Y
UNII	M84I3K7C2O
KEGG	D00833 Y C08002 Y
ChEBI	CHEBI:7566
ChEMBL	ChEMBL290960 N
CompTox Dashboard (EPA)	DTXSID3045439
ECHA InfoCard	100.041.377
Chemical and physical data
Formula	C10H13N3O5S
Molar mass	287.29 g·mol−1
3D model (JSmol)	Interactive image
Chirality	Racemic mixture
Melting point	180 to 182 °C (356 to 360 °F)
SMILES CC1CS(=O)(=O)CCN1N=CC2=CC=C(O2)[N+](=O)[O-]
InChI InChI=1S/C10H13N3O5S/c1-8-7-19(16,17)5-4-12(8)11-6-9-2-3-10(18-9)13(14)15/h2-3,6,8H,4-5,7H2,1H3 Y Key:ARFHIAQFJWUCFH-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Common side effects include abdominal pain, headache, nausea, and weight loss.[2] There are concerns from animal studies that it may increase the risk of cancer but these concerns have not been found in human trials.[5] Nifurtimox is not recommended in pregnancy or in those with significant kidney or liver problems.[5] It is a type of nitrofuran.[5]

Nifurtimox came into medication use in 1965.[5] It is on the World Health Organization's List of Essential Medicines.[4] It is not available commercially in Canada.[2] It was approved for medical use in the United States in August 2020.[3] In regions of the world where the disease is common nifurtimox is provided for free by the World Health Organization (WHO).[6]